UC Davis becomes first in region to grow cancer-fighting CAR T cells

Genetically modified cancer-fighting cells are now developed on campus as part of a new cellular therapy program


Alan Gaines did two tours in the Vietnam War as a Navy fighter pilot—so being brave isn’t new to him.  At 77, he was diagnosed with an aggressive blood cancer. When it failed to respond to treatment and his prognosis didn’t look good, he found his courage and his faith, as always.

That’s when UC Davis oncologist Joseph Tuscano asked if he’d like to try a clinical trial that involved removing cancer-fighting cells from his body and re-training them to attack his disease.  Essentially, his body’s own natural cancer killers, T cells, would be genetically modified to target the cancer.

Gaines’ bravery turned to excitement.

Dr. Joseph Tuscano examines Alan Gaines, first patient to receive CAR T cells grown at UC Davis Health
Alan Gaines, first patient to receive CAR T cells grown at UC Davis, and his wife Ann receive good news from oncologist Dr. Joseph Tuscano.

“I have a degree in engineering, and I know the importance of science,” said Gaines. “I told my wife, ‘Let’s go for it!’ because I thought if it doesn’t work for me it will help others down the road.”

Gaines had a form of lymphoma that was resistant to standard treatment and rapidly fatal without waging a formidable attack. Not only did the CAR T-cell therapy work for Gaines, but the retired commercial airline pilot became a pioneering patient. He received the first CAR T cells genetically manufactured on-site at UC Davis Health in Sacramento. The development comes as a new study shows that CAR T-cell therapy can cure leukemia

On a follow-up visit to the UC Davis Comprehensive Cancer Center on January 18, 2022, Gaines was given the remarkable news that his fast-growing type of Non-Hodgkin’s Lymphoma appears to be headed toward complete remission. Follow-up scans in two months will confirm.

“I was so excited to be able to tell Alan and his wife, Ann, that it worked,” said Tuscano, interim director of the UC Davis Stem Cell and Bone Marrow Transplantation Program. “I know how deadly this blood cancer can be and I want to give him the best chance to be cured. Alan is our first patient to take part in what is expected to be a very successful and robust cellular therapy program.”

T cell manufacturing at UC Davis

Tuscano credits UC Davis Health CEO David Lubarsky with “making the dream a reality” after nearly three years of planning for the launch of the CAR T-cell lab. UC Davis is now one of only a few medical centers in California manufacturing CAR T cells on site, and the only University of California campus doing so. 

“The results are early, but extremely promising,” said Lubarsky. “We are starting our CAR T-cell therapy program with blood cancers, but we anticipate using this revolutionary therapy as a breakthrough treatment for many other diseases in the not-too-distant future.” 

A gene manufacturing lab in the UC Davis Institute for Regenerative Cures, the Good Manufacturing Practice (GMP) Facility is where it all happens. The T cells removed from patients are transformed in the lab into super cells that target cancer with precision.

“It’s like a sci-fi story,” said Mehrad Abedi, an oncologist and professor at UC Davis who is the primary investigator for this trial. “T cells have receptors that are uniquely designed to latch onto cancer cells and then kill them by injecting them with toxins.  But sometimes the cancer cells dodge the T cells and that’s when the cancer grows. CAR T-cell therapy is often the only hope for patients who are given little to no chance of survival.”

David Lubarsky
We are starting our CAR T-cell therapy program with blood cancers, but we anticipate using this revolutionary therapy as a breakthrough treatment for many other diseases in the not-too-distant future.”UC Davis Health CEO David Lubarsky

The re-engineering of T cell receptors

Technically known as chimeric antigen receptor T-cell therapy, CAR T-cell therapy works by modifying the receptors of the T cells so they spot specific cancers—even if the crafty cancer cells try to stay hidden. It’s considered immunotherapy because it uses the body’s own defenses, its immune system, to fight disease.

The Food and Drug Administration first approved CAR T-cell therapy in 2017.

Rather than contracting with a commercial lab, which returns frozen T cells that require expensive transportation costs, CAR T cells that can be manufactured on site are key to more efficient and effective CART T-cell therapy.

Abedi said manufacturing the T cells at UC Davis provides a fresh product that will leave the T cells more “persistent and with a better memory of how to go after cancer cells.”

“We also think we can reduce the cost of CAR T-cell therapy by manufacturing on site,” said Abedi.  “Currently, commercial products can run as high as $500,000. By local manufacturing and removing the storage and transportation costs, we expect to get the cost down to as low as $50,000 per patient, which makes this product more affordable, even for insurance companies.”

“Giving more patients equal access to CAR T-cell therapy is important because we’re in the business of saving lives,” said Jan Nolta who directs the Institute of Regenerative Cures. “Cultivating these potent cancer killers in our own lab is opening the doors to innovation. We’re already looking at the cancers we want to tackle next, including ovarian, kidney and bladder cancers. As a cancer survivor myself I am particularly passionate about CAR-T therapy.”

From patient to lab and back to patient

T cells are first removed from a patient’s blood during a process called “leukapheresis.” The patient stays seated or lying down for two to three hours during the procedure. Sent to a lab via a mobile refrigerator, the T cells are then altered by adding a gene specific to the receptor. Over the course of several weeks, these CAR T cells are grown in the lab until they number in the millions.

Once they mature and amass into a lean, mean cancer-fighting machine, the CAR T cells are ready to be infused back into the patient. But first the patient goes through what’s called “lymphodepleting conditioning,” a type of chemotherapy that makes more room for the CAR T cells to expand as they conquer and destroy cancer cells.

“Our Phase I trial at UC Davis allows us to get more innovative about how we do CAR T-cell therapy. For example, because we can transform the T cells on site, we have better control over the quality of the product,” said Abedi. “We feel this is the best way to ensure the CAR T cells continue to grow, over the lifetime of the patient, providing a constant army of re-engineered T cells ready to attack any cancer cells that show up.”

In addition to providing access to all patients, the clinical trial is examining the precise dose of conditioning treatment before infusion of the cells. The goal is to determine the best way to ready the patients’ immune system for the new and improved T cells.

“The CAR T cells can persist long after the patient enters remission,” said Abedi.  “We think the conditioning prior to the re-infusion can improve the persistence of the cells in the body. That’s another reason why this Phase 1 clinical trial is so important.”

Careful monitoring required

CAR T-cell therapy is highly effective but comes with the risk of serious side effects. As the CAR T-cells multiply in the body, they can release chemicals called cytokines into the blood, which can cause the immune system to go awry. That’s why the treatment should only be given at a medical center that is specially trained in its use and why patients need to be monitored closely.

Patients stay at the hospital for at least a week after receiving treatment. For another month after leaving the hospital, patients need to stay near the medical facility for frequent follow-up appointments.

“We took advantage of the lodging accommodations on the UC Davis campus since we live in the Sierra foothills,” said Gaines.

Gaines’ wife Ann was by his side during the entire process.  Married more than 50 years, they used the time together in between follow up visits to plan for what they want to do next in their lives.

“The staff here at UC Davis is so caring and so positive,” said Ann. “We feel so confident now with Alan’s treatment behind us that we are looking ahead to hiking, biking, camping this summer and a possible cross-country trip in our travel trailer to visit our children and grandchildren.”

Her husband agreed, “I feel terrific. I’m here and I feel great,” said Gaines. “Fortunately, the only side effect for me was tiredness and a mild rash. Dr. Tuscano is a terrific supporter with a wonderful personality and a way of making sure we were well-informed every step of the way. I’m feeling very positive about the future.”

UC Davis staff working “behind the scenes” to launch the CAR T-cell therapy program

  • Naseem Esteghamat, hematologist oncologist
  • Grace Chan, stem cell transplant nurse coordinator, Bone Marrow Transplant Program
  • Gerhard Bauer, director of the GMP Facility
  • Brian Fury, manager of manufacturing, GMP Facility
  • Dane Coleal, manufacturing supervisor, GMP Facility
  • Jeannine White, advanced cell therapy project manager
  • Jordan Pavlic, cell manufacturer, GMP Facility
  • Geralyn Moser Annett, Alpha stem cell program manager
  • Trisha Yassear, Alpha Clinic operations manager
  • Erika Crawford, lead senior certified clinical research coordinator, Alpha Clinic
  • Nataly Magner, cell and gene therapy specialist, Alpha Clinic
  • Karen O'Donnell, cell and gene therapy specialist, Alpha Clinic
  • Ashley Ramsay, cell and gene therapy specialist, Alpha Clinic
  • Dara Feleciano, clinical research nurse, Alpha Clinic

UC Davis Medical Center is a comprehensive academic medical center where clinical practice, teaching and research converge to advance human health. Centers of excellence include the National Cancer Institute-designated UC Davis Comprehensive Cancer Center; the region's only Level 1 pediatric and adult trauma centers; the UC Davis MIND Institute, devoted to finding treatments and cures for neurodevelopmental disorders; and the UC Davis Children's Hospital. The medical center serves a 33-county, 65,000-square-mile area that stretches north to the Oregon border and east to Nevada. It further extends its reach through the award-winning telemedicine program, which gives remote, medically underserved communities throughout California unprecedented access to specialty and subspecialty care. For more information, visit